Search results for "Stem Cell"

showing 10 items of 2354 documents

Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell tra…

2020

BACKGROUND: Enterovirus/rhinoviruses (EvRh) are the most common cause of respiratory virus infections in recipients of allogeneic stem cell transplantation (allo-HSCT).; OBJECTIVE: We sought to analyze the value of the immunodeficiency scoring index (ISI) in predicting lower respiratory tract disease (LRTD) progression and mortality in a prospective cohort of consecutive adult (> 16 years) allo-HSCT recipients with EvRh infection from December 1 2013 to December 1 2019 at two Spanish transplant centers.; RESULTS: We included 234 allo-HSCT recipients with 383 EvRh episodes. Out of 383 EvRh episodes, 98 (25%) had LRTD. Multivariate logistic regression analysis identified three independent fac…

AdultMalemedicine.medical_specialtyAdolescentRhinovirusmedicine.medical_treatmentHematopoietic stem cell transplantationcommunity acquired respiratory virus030230 surgerymedicine.disease_cause03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineallogeneic stem celltrasplantationmedicineHumansTransplantation HomologousProspective StudiesProspective cohort studyRespiratory Tract InfectionsImmunodeficiencyimmunodeficiency scoring indexAgedRetrospective StudiesTransplantationPicornaviridae InfectionsRespiratory tract infectionsbusiness.industryHematopoietic Stem Cell TransplantationImmunologic Deficiency SyndromesRespiratory infectionMiddle Agedmedicine.diseaseTransplantationInfectious DiseasesrhinovirusROC CurveSpainMultivariate AnalysisRespiratory virus030211 gastroenterology & hepatologyFemaleRhinovirusbusiness
researchProduct

Effect of interleukin-3 pretreatment on granulocyte/macrophage colony-stimulating factor induced mobilization of circulating haemopoietic progenitor …

1995

Recombinant human colony stimulating factors (CSFs) as single agents are increasingly used for mobilizing peripheral blood progenitor cells (PBPCs) for stem cell transplantation. We have shown in rhesus monkeys that interleukin-3 (IL-3) pretreatment markedly potentiated the increase in PBPC numbers of subsequent administration of granulocyte/macrophage-CSF (GM-CSF). Here we studied the effect of IL-3 pretreatment on GM-CSF-induced mobilization of PB progenitors in patients who were potential candidates for autologous stem cell transplantation (n = 16). Patients were treated with GM-CSF at a dose of 5 micrograms/kg/d for 5 d and after a treatment free interval received another cycle of GM-CS…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentGranulocyteLeukocyte CountInternal medicinemedicineHumansProgenitor cellInterleukin 3business.industryPlatelet CountGranulocyte-Macrophage Colony-Stimulating FactorHematologyColony-stimulating factorHematopoietic Stem CellsTransplantationCytokineEndocrinologymedicine.anatomical_structureGranulocyte macrophage colony-stimulating factorImmunologyErythrocyte CountFemaleInterleukin-3Stem cellbusinessmedicine.drugBritish journal of haematology
researchProduct

Spontaneously‐resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and cli…

2018

It has been reported that low-plasma cytomegalovirus (CMV) DNA loads are associated with an increased risk of overall mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Utilizing a conservative strategy for initiation of preemptive antiviral therapy (>1500 IU/mL), we characterized the virological features of spontaneously-resolving episodes of CMV DNAemia and assessed their impact on mortality through the first year after transplantation. We reviewed the CMV DNA polymerase chain reaction results and clinical charts of 230 consecutive adult patients who underwent T-cell replete allo-HSCT at our center. A total of 280 episodes of CMV DNAemia were registered in 164 pa…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentRemission SpontaneousCongenital cytomegalovirus infectionCytomegalovirusHematopoietic stem cell transplantationGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineVirologyInternal medicinemedicineHumansTransplantation HomologousIn patient030212 general & internal medicineAgedRetrospective Studiesbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesCmv dnaemiaMiddle AgedViral Loadmedicine.diseaseVirologyTransplant RecipientsConservative strategyTransplantationInfectious DiseasesIncreased riskCytomegalovirus InfectionsDNA ViralFemale030211 gastroenterology & hepatologyAllogeneic hematopoietic stem cell transplantbusinessJournal of Medical Virology
researchProduct

Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German mu…

2002

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) mobilized peripheral blood progenitor cells (PBPCs) from healthy individuals are a rapidly emerging alternative source to bone marrow for allogeneic transplantation. Although widely applied in the meantime, only limited information on feasibility and safety of mobilization and collection of PBPCs is currently available from prospective multicenter studies specifically designed to investigate this donation modality. This ongoing multicenter study on the performance as well as the short- and long-term safety profile of rhG-CSF-induced mobilization and collection of PBPCs was initiated in October 1999. The study is designed to r…

AdultMalemedicine.medical_specialtyAllogeneic transplantationAdolescentFilgrastimAntigens CD34Blood DonorsFilgrastimImmunophenotypingNuclear FamilyInternal medicineGranulocyte Colony-Stimulating FactormedicineClinical endpointHumansLeukapheresisProspective StudiesProspective cohort studyAdverse effectbusiness.industryHematologyGeneral MedicineLeukapheresisMiddle AgedHematopoietic Stem Cell MobilizationLymphocyte SubsetsRecombinant ProteinsGranulocyte colony-stimulating factorSurgeryBlood Cell CountRegimenImmune SystemFemalebusinessmedicine.drugAnnals of hematology
researchProduct

Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML

1998

High-dose chemotherapy with autologous transplantation of in vivo purged PBSC is a new and interesting therapeutic option for CML patients not eligible for allogeneic transplantation. We investigated the feasibility and toxicity of this approach in 57 patients with Ph-positive CML. For mobilization of Ph-negative PBSC, patients were treated either with '5 + 2/7 + 3'- type chemotherapy or with 'mini-ICE/ICE' chemotherapy followed by administration of G-CSF. Fourteen patients were in early chronic phase, 30 patients in late chronic phase and 13 patients in accelerated phase (AP) or blast crisis (BC). Cytogenetic responses in the PBSC harvests were dependent on both disease stage and type of c…

AdultMalemedicine.medical_specialtyAllogeneic transplantationmedicine.medical_treatmentPilot ProjectsLeukemia Myelogenous Chronic BCR-ABL PositiveAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAutologous transplantationProspective StudiesEtoposideTransplantationMyelosuppressive ChemotherapyChemotherapybusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell MobilizationGranulocyte colony-stimulating factorSurgeryTransplantationKaryotypingCytarabineFemalebusinessmedicine.drugBone Marrow Transplantation
researchProduct

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation

2011

Antifungal prophylaxis for allogeneic haematopoietic stem-cell transplant (alloHCT) recipients should prevent invasive mould and yeast infections (IFIs) and be well tolerated. This prospective, randomized, open-label, multicentre study compared the efficacy and safety of voriconazole (234 patients) versus itraconazole (255 patients) in alloHCT recipients. The primary composite endpoint, success of prophylaxis, incorporated ability to tolerate study drug for ≥100 d (with ≤14 d interruption) with survival to day 180 without proven/probable IFI. Success of prophylaxis was significantly higher with voriconazole than itraconazole (48·7% vs. 33·2%, P 10%) treatment-related adverse events were vom…

AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentItraconazoleazolesstem-cell transplantPharmacologyBiologyAspergillosisGastroenterologyYoung AdultInternal medicineAmphotericin BmedicineHumansTransplantation Homologousyeast infectionsProspective StudiesChildAdverse effectAgedVoriconazoleHaematological MalignancyHematopoietic Stem Cell TransplantationHematologyMiddle AgedTriazolesmedicine.diseaseinvasive fungal diseaseTransplantationPyrimidinesMycosesmould infectionsFemaleVoriconazoleLiver functionItraconazoleFluconazolemedicine.drugBritish Journal of Haematology
researchProduct

Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Res…

2010

Caspofungin at standard dose was evaluated as first-line monotherapy of mycologically documented probable/proven invasive aspergillosis (IA) (unmodified European Organisation for Research and Treatment of Cancer/Mycosis Study Group criteria) in allogeneic hematopoietic SCT patients. The primary efficacy end point was complete or partial response at end of caspofungin treatment. Response at week 12, survival and safety were additional end points. Enrollment was stopped prematurely because of low accrual, with 42 enrolled and 24 eligible, giving the study a power of 85%. Transplant was from unrelated donors in 16 patients; acute or chronic GVHD was present in 15. In all, 12 patients were neut…

AdultMalemedicine.medical_specialtyAntifungal AgentsDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationAspergillosischemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultPharmacotherapyCaspofunginInternal medicineMedicineAspergillosisHumansTransplantation HomologousaspergillosiscaspofunginAdverse effectSurvival rateAgedallogeneicTransplantationbusiness.industryHematopoietic Stem Cell Transplantationhematopoietic SCTHematologyMiddle Agedmedicine.diseaseSurgeryCalcineurinTransplantationEuropeSurvival RateTreatment OutcomechemistryDrug Therapy CombinationFemaleCaspofunginbusinessBone marrow transplantation
researchProduct

Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobil…

2005

The optimal approach to obtain an adequate graft for transplantation in patients with poor peripheral blood stem cell (PBSC) mobilization remains unclear. We retrospectively assessed the impact of different strategies of second-line stem cell harvest on the transplantation outcome of patients who failed PBSC mobilization in our institution. Such patients were distributed into three groups: those who proceeded to steady-state bone marrow (BM) collection (group A, n = 34); those who underwent second PBSC mobilization (group B, n = 41); those in whom no further harvesting was carried out (group C, n = 30). PBSC harvest yielded significantly more CD34+ cells than BM collection. Autologous trans…

AdultMalemedicine.medical_specialtyAntigens CD34Bone Marrow CellsCell CountTransplantation AutologousInternal medicineGranulocyte Colony-Stimulating FactorMedicineAutologous transplantationHumansLeukapheresisHematopoietic Stem Cell MobilizationAgedBone Marrow TransplantationRetrospective StudiesTransplantationPeripheral Blood Stem Cell TransplantationHematologyBlood Cellsbusiness.industryHematologyLeukapheresisMiddle AgedHematopoietic Stem Cell MobilizationGranulocyte colony-stimulating factorSurgeryTransplantationmedicine.anatomical_structureTreatment OutcomeHematologic NeoplasmsFemaleBone marrowStem cellbusinessBone marrow transplantation
researchProduct

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findin…

2018

Patients with primary refractory or relapsed acute myeloid leukemia (RR-AML) have very poor prognosis. Due to limited treatment options, some patients are treated with hypomethylating agents (HMAs) due to their tolerability. Little is known about the role of allogeneic hematopoietic stem cell transplantation (HSCT) following HMA therapy in this setting. We retrospectively analyzed an international cohort of 655 RR-AML patients who received HMA therapy to study patterns and outcomes with HSCT. Only 37 patients (5.6%) patients underwent HSCT after HMA therapy. The conditioning regimen was myeloablative in 57% and nonmyeloablative in 43%. Patients received matched unrelated donor, matched sibl…

AdultMalemedicine.medical_specialtyAntimetabolites AntineoplasticTransplantation ConditioningSurvivalmedicine.medical_treatmentSalvage therapyGraft vs Host DiseaseHypomethylating agentsHematopoietic stem cell transplantationTransplant03 medical and health sciences0302 clinical medicineRefractoryAMLimmune system diseasesInternal medicinehemic and lymphatic diseasesmedicineHumansTransplantation HomologousSurvival analysisAgedRetrospective StudiesSalvage TherapyTransplantationAML; Hypomethylating agents; Survival; Transplant; Adult; Aged; Antimetabolites Antineoplastic; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia Myeloid Acute; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation Homologousbusiness.industryHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyMiddle AgedSurvival AnalysisLeukemia Myeloid Acutesurgical procedures operativeTolerability030220 oncology & carcinogenesisCohortFemaleTransplantation Conditioningbusiness030215 immunology
researchProduct

Binding of monocytes from normolipidemic hyperglycemic patients with type 1 diabetes to endothelial cells is increased in vitro.

2009

Increased endothelial binding and emigration of monocytes play a dominant role in the pathogenesis of atherosclerosis in diabetes mellitus. Previous studies revealed that hyperlipidemia correlates with monocyte binding in vitro. The aim of this study was to characterize the monocyte-endothelial interaction of leucocytes of hyperglycemic patients with type 1 diabetes but lacking hyperlipidemia. We isolated monocytes from healthy controls and normolipidemic type 1 diabetes patients with elevated levels of HbA1c and quantified monocyte binding by an immunoilluminometric cell adhesion assay. Purity of isolated monocytes was at least 98%. Endothelial binding of monocytes from patients with type …

AdultMalemedicine.medical_specialtyArteriosclerosisEndocrinology Diabetes and MetabolismCell CountMonocytesPathogenesischemistry.chemical_compoundEndocrinologyInternal medicineDiabetes mellitusHyperlipidemiaInternal MedicinemedicineCell AdhesionHumansType 1 diabetesbusiness.industryCD11 AntigensImmunomagnetic SeparationMonocyteAntibodies MonoclonalGeneral Medicinemedicine.diseaseFlow CytometryIn vitroEndothelial stem cellEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 1GlucoseL-GlucosechemistryHyperglycemiaLuminescent MeasurementsMultivariate AnalysisRegression AnalysisFemaleEndothelium VascularbusinessExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct